Get the Stockscreener App
0.835
0.12%
-0.001
After Hours:
.86
0.025
+2.99%
Context Therapeutics Inc stock is traded at $0.835, with a volume of 42,912.
It is down -0.12% in the last 24 hours and up +22.79% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$0.836
Open:
$0.85
24h Volume:
42,912
Relative Volume:
0.23
Market Cap:
$74.90M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.9176
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+1.78%
1M Performance:
+22.79%
6M Performance:
+21.01%
1Y Performance:
-61.16%
1-Day Range:
$0.81
$0.8599
1-Week Range:
$0.81
$0.8849
52-Week Range:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.835 | 76.27M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Context Therapeutics Inc.’s volatility index tracking explainedQuarterly Trade Report & Safe Entry Momentum Tips - Newser
Can trapped investors hope for a rebound in Context Therapeutics Inc.July 2025 Weekly Recap & Fast Momentum Entry Tips - Newser
What moving averages say about Context Therapeutics Inc.2025 Trading Recap & Free Long-Term Investment Growth Plans - Newser
Analyzing drawdowns of Context Therapeutics Inc. with statistical tools2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - Newser
Is Context Therapeutics Inc. forming a reversal patternAnalyst Upgrade & Scalable Portfolio Growth Methods - Newser
Earnings visualization tools for Context Therapeutics Inc.Market Sentiment Review & Free High Return Stock Watch Alerts - Newser
Institutional scanner results for Context Therapeutics Inc.Portfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Key metrics from Context Therapeutics Inc.’s quarterly data2025 Volatility Report & Safe Capital Growth Plans - Newser
How to escape a deep drawdown in Context Therapeutics Inc.Portfolio Performance Summary & Weekly Market Pulse Alerts - Newser
Heatmap analysis for Context Therapeutics Inc. and competitorsWeekly Stock Report & Daily Profit Maximizing Tips - Newser
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average PT from Brokerages - Defense World
Top chart patterns to watch in Context Therapeutics Inc.Market Performance Summary & Weekly High Potential Alerts - Newser
Measuring Context Therapeutics Inc.’s beta against major indices2025 Top Gainers & Technical Pattern Alert System - Newser
Can momentum traders help lift Context Therapeutics Inc.July 2025 Sentiment & Accurate Technical Buy Alerts - Newser
Order flow analysis tools used on Context Therapeutics Inc.Weekly Trend Recap & High Accuracy Swing Trade Signals - Newser
Context Therapeutics Inc. stock volume spike explainedEarnings Recap Report & Low Risk Entry Point Tips - Newser
Short interest data insights for Context Therapeutics Inc.2025 Geopolitical Influence & Low Risk High Reward Ideas - Newser
Real time pattern detection on Context Therapeutics Inc. stockLong Setup & Weekly Watchlist of Top Performers - Newser
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average PT from Analysts - MarketBeat
Using data filters to optimize entry into Context Therapeutics Inc.Weekly Stock Analysis & Technical Pattern Based Signals - Newser
Best data tools to analyze Context Therapeutics Inc. stock2025 Volatility Report & AI Powered Market Trend Analysis - Newser
How to manage a losing position in Context Therapeutics Inc.Trade Ideas & Verified Chart Pattern Trade Signals - Newser
Is it time to cut losses on Context Therapeutics Inc.Market Trend Summary & Verified Entry Point Detection - Newser
Visual analytics tools that track Context Therapeutics Inc. performanceJuly 2025 Patterns & Reliable Momentum Entry Alerts - Newser
Is Context Therapeutics Inc. reversing from oversold territory2025 Risk Factors & Daily Profit Maximizing Tips - Newser
Market reaction to Context Therapeutics Inc.’s recent news2025 Short Interest & Safe Swing Trade Setup Alerts - Newser
Will Context Therapeutics Inc. stock go up in YEARQuarterly Trade Summary & Community Supported Trade Ideas - Lancaster City Council
Price action breakdown for Context Therapeutics Inc.Dip Buying & High Accuracy Swing Entry Alerts - Newser
News impact scoring models applied to Context Therapeutics Inc.Share Buyback & Safe Entry Point Alerts - Newser
Published on: 2025-09-09 01:57:25 - Newser
Is Context Therapeutics Inc. forming a bottoming baseWeekly Loss Report & Consistent Return Strategy Ideas - Newser
What high frequency data says about Context Therapeutics Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - Newser
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):